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ABSTRACT
Objective. Cardiopulmonary exercise 
test (CPET) is a widely used examina-
tion to predict the prognosis of many 
chronic pulmonary diseases, and it has 
also been tested in systemic sclerosis 
(SSc) with a focus on the development 
of pulmonary hypertension. CPET is 
a highly informative non-invasive tool 
that provides a more complex informa-
tion than conventional lung function 
tests to predict the course of cardiopul-
monary diseases, as it provides a gener-
al overview of the aerobic metabolism, 
influenced by pulmonary, cardiovascu-
lar and peripheral muscle function. The 
purpose of this investigation was to as-
sess if the progression and the develop-
ment of poor overall disease outcome in 
SSc can be predicted by this method. 
Methods. Twenty-nine SSc patients 
were investigated prospectively with 
standard follow-up plus CPET for a 
mean of 3.7 years to match the results of 
conventional evaluation modalities and 
CPET. A composite end-point of several 
serious outcomes reflecting SSc-related 
vascular and cardiopulmonary dam-
age was set up, and the predictive value 
of and correlations between the CPET 
parameters and resting lung function 
and echocardiography variables were 
assessed. 
Results. None of the clinical param-
eters, resting lung function or echocar-
diographic test results proved to be pre-
dictive of the development of the end-
point of poor prognosis in this cohort. 
In contrast, several CPET parameters 
were found to discriminate between 
SSc patients with or without adverse 
outcome. The detection of desaturation 
(at any CPET test) was associated with 
a higher risk of poor prognosis (OR: 
5.265). VO2 and VE/VCO2 at baseline 
correlated with the annual decrease 
in FVC, anaerobic threshold with the 
development of digital ulcers, and VE/
VO2 with the increase in pulmonary 
arterial pressure.
Conclusion. Several CPET parameters 
obtained at the beginning of follow-up 
are informative of the appearance of 
various adverse end-points. CPET is 
a feasible examination in the care of 
SSc patients and provides excess infor-
mation to current standard follow-up 
examinations.
Introduction
Systemic sclerosis (SSc), also termed 
scleroderma, is a systemic autoimmune 
disease with multi-organ involvement 
and frequently with a destructive, pro-
gressive disease course. Key pathways 
in the pathogenesis are vascular, fi-
brotic and immunological dysfunction, 
leading to progressive organ damage 
and increased mortality (1, 2). Leading 
causes of morbidity and mortality are 
interstitial lung disease (ILD), pulmo-
nary arterial hypertension (PAH) and 
obliterative vasculopathy, in particular 
digital ulcers, gangraene and macro-
vascular complications. Predictors of 
such poor outcome are hard to defini-
tively identify by the physician at the 
first encounter, but it is obviously of 
crucial importance in the determination 
of follow-up strategy and of the inten-
sity of immunosuppressive therapy. 
Current guidelines prompt the treating 
physicians to regularly (every 6 to 12 
months) perform resting lung function 
tests, high-resolution computed tomo-
graphy (HRCT) of the lung and resting 
echocardiography to estimate disease 
progression (3-5).
Cardiopulmonary exercise test (CPET) 
is a widely used examination to predict 
the prognosis of chronic obstructive 
pulmonary disease (6), post-transplant 
lung dysfunction (7, 8), or PAH (9, 10), 
and it has also been examined in pa-
tients suffering from SSc in the context 
of circulatory dysfunction, PAH, and 
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exercise-triggered left ventricular di-
astolic disorder (11-22). As CPET pro-
vides a general overview of the aerobic 
metabolism, influenced by pulmonary, 
cardiac and vascular function (23), the 
purpose of this investigation was to as-
sess if the development of poor over-
all disease outcome could be predicted 
by this non-invasive examination, and 
whether CPET may provide additional 
prognostic information to standard rest-
ing follow-up examinations. As the 
complexity of the disease is based upon 
the various individual organ involve-
ments, we hypothesised that this syn-
thetical examination is useful to survey 
the actual state of aerobic metabolism 
and predict the development of poten-
tial organ failures. As the predictive 
value of CPET has not been studied in 
SSc, neither to the progression of the 
individual organ damage nor to mor-
tality, we have initiated a prospective 
study with a focus on patients of a rela-
tively short disease duration and with-
out advanced-stage organ damage. Our 
aim was to assess correlations between 
CPET and traditional measurements, 
and to compare the predictive ability of 




Twenty-nine patients were consecu-
tively enrolled at the Department of 
Rheumatology and Immunology, Uni-
versity of Szeged, Hungary into this 
prospective study from 2010 to 2017. 
The diagnosis of SSc had been set up 
by ACR/EULAR diagnostic criteria 
(24). The standard exclusion criteria of 
CPET (NYHA stage III-IV heart fail-
ure, neurological comorbidities and 
unstable blood pressure) were applied, 
as well as severe musculoskeletal in-
volvement, which had led to inability 
to participate at the examination. Each 
patient had at least two CPET exami-
nations with at least one year differ-
ence. A composite end point was set 
up to define poor disease outcome. 
Our composite end point comprised: 
death, digital ulceration necessitating 
endothelin receptor antagonist therapy, 
pulmonary hypertension (estimated 
systolic pulmonary arterial pressure /
PAP/ >40mmHg), change of carbon-
monoxide diffusion capacity (deltaDL-
CO) >2%/year, or change in PAP (del-
taPAP) >3mmHg/year. 
Procedures
All patients attended spirometry to 
measure dynamic lung volumes (forced 
vital capacity, /FVC/ and forced ex-
piratory volume in 1 s, /FEV1/), body 
pletysmography to measure total lung 
capacity /TLC/, and the measurement 
of diffusing capacity of the lung meas-
ured by carbon monoxide (DLCO), 
which informs about alveolo-capillary 
gas exchange. Regular, yearly non-
invasive examinations were performed 
in parallel with the CPETs. The pres-
ence, extent and activity of interstitial 
lung disease were assessed by HRCT, 
to explore (subclinical) alveolitis and 
progression of pulmonary fibrosis. 
Chest HRCT was performed at the first 
visit, and repeated if necessitated by 
worsening lung function tests or other 
relevant clinical findings. HRCT inter-
pretation was based on visual analysis. 
The examinations, evaluated by expe-
rienced senior radiologists, determined 
the presence and distribution of the 
following CT signs suggestive of SSc 
involvement: Alveolitis was verified if 
areas of isolated ground-glass opaci-
ties were observed on high-resolution 
chest CT (HRCT) scans. Fibrosis was 
diagnosed when fine or coarser re-
ticular pattern of pathology was noted 
within areas of ground-glass opacities, 
with or without honeycombing, traction 
bronchiectasis and/or bronchiolectasis. 
Estimated pulmonary pressure was fol-
lowed by echocardiography once year-
ly, or at six-month intervals if neces-
sitated by the clinical course. Systolic 
PAP values >40 mmHg were regarded 
as pulmonary hypertension (PH). We 
avoided the use of pulmonary arterial 
hypertension (PAH) in this study, since 
the primary focus of this study was not 
the specific examination in changes in 
PAP, but rather of a composite end-
point as mentioned above, and there-
fore we regarded it ethical to perform 
right heart catheterisation only in the 
event of a significant elevation of PAP 
(>50 mmHg), as in routine care, follow-
ing national guidelines. We therefore 
used the term pulmonary hypertension 
(PH). The same cardiologist performed 
all the echocardiographic examinations 
in order to eliminate inter-observer var-
iability. In addition to the above-listed 
examinations, patients were under reg-
ular gastroenterological surveillance to 
upper gastrointestinal involvement, in-
cluding gastrointestinal reflux disease 
(GERD), Barrett’s metaplasia or gastric 
antral vascular ectasia, following inter-
national guidelines (25, 26).
Resting lung function and CPET meas-
urements were performed at the De-
partment of Pulmonology, University 
of Szeged. Spirometry, body pletys-
mography and DLCO measurements 
were carried out on a Vmax229 Auto-
box 6200 (Sensormedics, Yorba Linda, 
California) equipment. Normal values 
were defined by NHANES (National 
Health and Nutrition Examination Sur-
vey) (27). Systolic PAP was estimated 
from the degree of tricuspid valve re-
gurgitation by echocardiography. Other 
parameters of left ventricular systolic 
(ejection fraction), diastolic (E/A ratio) 
and right ventricular systolic (tricus-
pid annular plane systolic excursion – 
TAPSE) function were also recorded.
CPET was implemented on a bicycle 
ergometer with an electric brake (Er-
goline 900) by continuously increasing 
(RAMP) load. A three-minute resting 
phase was followed by a three-minute 
consistent intensity warm-up phase 
on 20 W, next the performance was 
raised by 10 W/min consistently. Tid-
al volume (VT), expired volume (VE), 
oxygen uptake (VO2), carbon dioxide 
production (VCO2) were measured 
breath by breath by a mass flow me-
ter on a metabolic load system (VMAX 
29C Respiratory Analyzer, Sensormed-
ics). Before every test, the system had 
been calibrated. Anaerobic threshold 
(AT) was defined by V-slope method. 
Heart rate, twelve-lead ECG (Cardi-
osoft, Sensormedics) and oxygen satu-
ration (SatTrak, Sensormedics) were 
monitored during the tests. No medi-
cation was interrupted in the period of 
the test. Breathing reserve (BR%) was 
determined and if the value was 15% 
or below, it indicated that the test was 
ventilation-limited. Heart rate reserve 
(HRR%) was also defined, and in cases 
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in which the value was 10% or below, 
circulation-limited exercise capacity 
was considered. In the present study, the 
following parameters were analysed: 
peak workrate (Wmax [Watt]), heart rate 
(HR), aerobic capacity as measured by 
oxygen uptake (VO2 [L/min]), specific 
aerobic capacity (VO2/kg [mL/min/
kg]), carbon dioxide output (VCO2 [L/
min]), minute ventilation (VE [ref%]), 
anaerobic threshold (AT [L/min]), oxy-
gen saturation at rest, oxygen saturation 
at maximum load (SpO2), and the dif-
ference of these two values (desatura-
tion), respiratory equivalent for carbon 
dioxide output (VE/VCO2) determined 
at anaerobic threshold, which inform 
about ventilator efficiency (ventilation-
perfusion mismatch). Normal values 
were the following: VO2max> 84 ref%, 
AT (VO2 at AT / VO2pred,max) >40%, HR-
max: > 90% of the expected maximum 
(calculated by 220-age/years/), VE/
VCO2<30. Following the American 
Medical Association (AMA) standard-
ised values, if VO2max is between 15 and 
20 mL/kg/min or DLCO is between 41 
and 59%, pulmonary functional dam-
age is between 26 and 50%. If VO2max is 
<15 mL/kg/min or DLCO is <40%, the 
degree of pulmonary damage is more 
than 50% (27). In healthy individuals, 
SpO2 and the partial pressure of oxy-
gen in arterial blood remain stable dur-
ing exercise, and saturation does not 
decrease more than 2%. Desaturation 
means SpO2 decreases ≥4% or becomes 
less than 88% (i.e. it is a categorical 
variable). The maximum difference 
(change) in SpO2 during exercise (i.e. 
the degree of desaturation) is represent-
ed as DeltaSatmax (i.e. it is a continuous 
variable).
Statistical methods
Continuous variables were compared 
between groups with t-test or analysis 
of variance, or, in the event of non-
normal distribution of the values, with 
Mann-Whitney U-test. Categorical 
variables, including frequencies, were 
compared with chi2 test. The predictive 
value of baseline categorical variables 
was assessed with Fisher exact test, 
where the odds ratio of the develop-
ment of the endpoint was determined. 
The predictive value of continuous 
variables was estimated with receiver-
operated curve (ROC) analysis. Corre-
lations between certain CPET param-
eters with resting lung function tests or 
clinical variables were examined with 
Pearson’s correlation test. For the anal-
ysis of the association between certain 
continuous variables and the develop-
ment of the end-point, logistic regres-
sion was applied. A p-value of <0.05 




Demographic data, organ manifesta-
tions, autoantibody-positivities and 
some specific immunosuppressive or 
vasoactive medications applied in the 
patients are presented in Table I. Dif-
fuse and limited cutaneous SSc sub-
sets were represented in comparable 
numbers, and the disease had a rela-
tively short duration from the onset of 
the first non-Raynaud symptom, with 
some exceptions. Immunosuppressive 
therapy was applied in the majority of 
the patients, especially in those with 
dcSSc, as per international guidelines, 
with rapid progression of skin involve-
ment, ILD or some other inflammatory 
manifestations of the disease being the 
most frequent indications. ILD was 
detected with HRCT in more than half 
of the patients, whereas the prevalence 
of PH was relatively low. Scleroderma 
renal crisis did not occur ever in the en-
rolled patients. 
In addition to anti-Scl-70 and anti-
centromere antibodies, other autoanti-
body positivities have been revealed in 
a total of 6 patients: anti-nucleosome 
antibody (n=4), anti-SSA/Ro (n=3), 
anti-mutated citrullinated vimentin 
(n=2), and anti-double stranded DNA 
(n=2). We note that we did not examine 
further SSc-specific autoantibodies in 
this cohort. Four patients fulfilled the 
criteria of another autoimmune disease 
too: two patients had an overlapping 
rheumatoid arthritis (RA), one had sys-
temic lupus erythematosus (SLE), and 
one had myositis. The overlapping RA 
or SLE were in remission at study en-
try, and occasional relapses manifest-
ed as polyarthritis responded well to 
transient low dose corticosteroid, and 
to immunosuppressive therapies indi-
cated for SSc. The overlapping myosi-
tis was also controlled throughout the 
follow-up and did not lead to signifi-
cant muscle atrophy. We did not clas-
sify any of the patients with Sjögren’s 
syndrome overlap. 
Immunosuppressive therapy was ap-
plied in the majority of the patients, 
especially in those with dcSSc, as per 
international guidelines, with rapid pro-
Table I. Clinical characteristics of the SSc cohort.
Age (yr) 49  (16-68)
Female : male (n) 24:5
DcSSc : LcSSc (n) 15:14
anti-Scl-70: anti-centromere-B antibody positivity (n) 14:5
Time since Raynaud’s phenomenon (yr) 8.2  (1-28)
Time since first non-Raynaud symptom (yr) 4.8  (0-28)
Alveolitis (n) 15
Lung fibrosis(n) 16
Pulmonary hypertension (n) 10




Barrett oesophagus (n) 21
GAVE (n) 5
Motility disorder (n) 11
Hypercholesterolaemia (n) 6
Hypertension (systemic) (n) 7
Immunsupressive therapy (n) 18
Endothelin receptor antagonist therapy 5
Malignancy (n) 2
Overlap syndrome (n) 4
Numbers indicate mean (range) or absolute numbers.
GERD: gastro-oesophageal reflux disease; GAVE: gastric antral vascular ectasia.
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gression of skin involvement, ILD or 
some other inflammatory manifestations 
of the disease being the most frequent 
indications. A detailed presentation of 
the medications of the patients, includ-
ing immunosuppressants, cardiovas-
cular agents (indicated for Raynaud’s 
phenomenon or systemic hypertension), 
treatment of obstructive airway symp-
toms and other are presented in Sup-
plementary Table S1. Changes in these 
treatments were made for immunosup-
pressants as required by the clinical 
course of SSc, and in a few cases for the 
cardiovascular medication, but we note 
that none of them were specifically in-
dicated for pulmonary hypertension or 
congestive heart failure.
The patients were followed-up for a 
median of 94 (range: 33-110) months. 
An average of 3.93 (range: 2-8) lung 
function and CPET examinations were 
performed per patient. During the 
study period, one patient died (sudden 
cardiac death, advanced microvascular 
damage, lung and myocardium fibro-
sis), five received endothelin-antago-
nist treatment necessitated by recur-
rent, severe digital ulcerations, in three 
of them did the estimated PAP increase 
to values over 40 mmHg, in 4 of them 
was the annual increase of PAP higher 
than 3 mmHg, and in 12 patients was 
the annual decline of DLCO higher 
than 2%. Overall, 16 patients met the 
pre-defined endpoint of a severe dis-
ease outcome. Comparisons between 
the groups who did and who did not 
meet the endpoint revealed no statisti-
cally significant difference in terms of 
age, gender, dcSSc versus lcSSc sub-
set, disease duration, the presence of 
ILD, PH, digital ulcer or calcinosis.
Resting lung function 
tests and PAP measurements
Resting lung function test and echocar-
diography results at enrolment and dur-
ing follow-up are summarised in Table 
II. Pletysmographic values were, on 
average, close to the normal range, but 
with significant variability, and mark-
edly decreased lung volumes were also 
noted in a few patients. In contrast, 
mean DLCO value was in the mod-
erately decreased range, again, with 
high variability. PAP values were in the 
normal or moderately elevated range. 
Annual changes in the DLCO and PAP 
values were, on average, modest, but 
changes in both directions occurred 
during follow-up. When the direction 
of worsening was examined separately, 
decreasing DLCO was observed in 19 
of the 29 patients, whereas PAP in-
creased in 10 of 14 patients in whom 
repeated PAP measurements could be 
performed. It is to be noted that PAP 
was estimated from the degree of tri-
cuspid regurgitation, and, therefore, 
was not feasible to assess in the ab-
sence of tricuspid retrograde blood 
flow. None of the resting parameters, 
nor their changes displayed a statisti-
cally significant difference between the 
subgroups with or without meeting the 
end-point.
Cardiopulmonary exercise test results 
Mean values and ranges of the CPET 
results at first and last visits of the 
study are presented in Table III.
It can be concluded that the values at 
inclusion reflect moderately decreased 
work-rate and aerobic capacity with 
slightly impaired ventilation-perfusion 
mismatch (higher VE/VCO2) compared 
to age-matched healthy individuals. 
Baseline desaturation (i.e. a drop in 
SpO2 of at least 4% during the exercise 
test) occurred in 6 patients, and during 
follow-up, it was detected in further 8 
patients. The degree of desaturation 
Table II. Summary of the most important resting lung function and pulmonary arterial 
pressure values at baseline, and the change of selected variables.
Parameter Mean or median Range SD or 25th-75th  
   percentile
FVC (% of predicted) 94.2 54 – 125 17.8
FVC (L) 3.06 1.97 – 5.26 0.72
TLC(% of predicted) 90.9 47 - 117 17.7
TLC (L) 4.75 3.08 – 6.14 0.75
DLCO (% of predicted) 56.8 20 – 94 16.9
DLCO (ml/min/mmHg) 14.51 4.60 – 30.10 5.16
DeltaFVC/year (L)  -0.02 -0.19 – +0.31 -0.08 – +0.05
DeltaDLCO/year (ml/min/mmHg)  -0.43 -5.92 – +2.68 -0.75 – +0.36
PAP (mmHg) 28.5 18 – 44 7.4
deltaPAP/year (mmHg) 1.2 -8 - +12 4.5
FVC: forced vital capacity; DLCO: diffusion capacity of carbon monoxide; TLC: total lung capac-
ity; PAP: pulmonary arterial pressure; L: litre. Delta values indicate changes from the first to the last 
measurement.
Values are presented as mean, range and SD (normal distribution) or median range and 25th and 75th 
percentile (non-normal distribution – in italics).
Table III. Cardiopulmonary exercise test results. 
Parameter First measurement Last measurement Annual  
   change
WR 101.4 46-187 98.52 62-189 -0.09
VO2 (L/min) 1.34 0.5-2.4 1.47 0.84-2.81 0.03
VCO2 (L/min )   1.485 0.45-2.53 1.58 0.83-2.79 0.04
VO2/kg(ml/min/kg) 19.64 9-5-36.5 20.2 10.7-33.1 0.43
VE(L/min) 51.42 17.6-85.6 48.3 28.1-83.5 -0.74
VE/VCO2 33.24 26-42 29.43 21-44 -0.85*
AT (L/min) 1.00 0.58-1.91 0.92 0.46-1.67 -0.02
AT (%  of VO2max,pred) 47.96 25-77 46.04 25-69 -0.39
DeltaSatmax (Decrease in SpO2) (%) 4.5 1-12 5 1-12 0.12
Desaturation (n) 6 14 
WR: workrate; VO2: aerobic capacity; VO2/kg: specific aerobic capacity; VCO2: CO2 output; VE: 
minute ventilation; VE/VCO2: respiratory equivalent for CO2output; AT: anaerobic threshold (L/min), 
AT% (% of predicted VO2max); SpO2: haemoglobin O2 saturation measured by pulse-oximetry. De-
crease in SpO2 indicates the degree of desaturation, whereas Desaturation denotes the number of pa-
tients in whom desaturation (decrease in SpO2  ≥ 4%) occurred ever during follow-up. Comparison of 
values at first and last visits. Numbers indicate mean (first and third column) and range (second and 
fourth column) or absolute number of involved patients.
*p<0.05 between first and last visit results.
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(mean change in SatO2 during CPET) 
did not change significantly during 
follow-up. Anaerobic threshold values 
were close to normal both at baseline 
and follow-up. Average changes in the 
different variables were relatively small 
indicating relatively stable cardiopul-
monary function during exercise at the 
group level. Significant decrease in the 
VE/VCO2 values during follow-up re-
vealed improved ventilator efficiency.
In order to confirm the clinical validity 
of CPET in our SSc cohort, first we cor-
related the values of its parameters at 
enrolment with the resting lung function 
test results measured at the same time. 
Significant correlations (p<0.05) are 
presented in Table IV (second column). 
Many of the baseline CPET param-
eters correlated with baseline DLCO 
(in most instances with both absolute 
values expressed in ml/min/mmHg and 
% of predicted values), a gold-standard 
parameter most commonly used during 
the follow-up of SSc patients to screen 
for and monitor pulmonary parenchy-
mal or vascular progression. As it can 
be seen, WR, VO2, VO2/kg, VE, AT and 
AT% all correlated positively, whereas 
VE/VCO2 negatively with DLCO, indi-
cating that CPET is a feasible and valid 
examination also in SSc patients, cor-
relating well with the well-established 
measurement method of gas exchange. 
WR, VO2, VO2/kg, VE and AT also pos-
itively correlated with FVC.
Next, we assessed the correlation be-
tween baseline CPET variables and 
several scleroderma-specific clinical 
outcome variables, as our aim was to 
examine whether CPET performed at 
the diagnosis of SSc may identify dis-
ease parameters that require special 
focus during follow-up. Demographic 
data, clinical parameters included in the 
composite end-point, and the annual 
decrease in DLCO, FVC and desatura-
tion were analysed, the latter three were 
selected because they are of special im-
portance with regard to disease progres-
sion (2). These data are also presented 
in Table IV (third column). Lower 
AT% and higher DeltaSatmax correlated 
with the development of digital ulcers. 
Higher VE/VO2 values were in asso-
ciation with a higher annual increase 
in PAP. A higher decline in FVC during 
follow up correlated with higher VO2 
and lower VE/VCO2 values at baseline. 
Furthermore, the presence of desatura-
tion at baseline also positively correlat-
ed with the subsequent annual change 
(increase) in the degree of desaturation 
(r=+0.57, p<0.05, data not shown). Not 
only the baseline value of desatura-
tion (DeltaSatmax), but also its annual 
change (i.e. increase) correlated with 
the annual change in DLCO (p<0.05, 
data not shown). Finally, age correlated 
negatively (data not shown), whereas 
disease duration positively with several 
CPET parameters.
As mentioned before, the complexity 
of CPET offers the opportunity to use it 
as a general predictor of poor prognosis 
is SSc. We therefore compared the two 
patient groups separated as to whether 
the patients met the serious outcome 
endpoint (endpoint+, n=16) or did not 
meet it (endpoint-, n=13). Selected pa-
rameters are presented in Table V. None 
of the clinical variables were different 
among the two groups, and although 
the dcSSc subset and patients with ILD 
were apparently represented in higher 
prevalence in the endpoint+ group, not 
even this comparison was statistically 
significant. PAP was also comparable in 
the two patient groups. Similarly, none 
of the resting lung function test vari-
ables either as measured at enrolment, 
nor the change in any of the parameters, 
were found to differentiate patients 
with poor outcome from those with a 
better prognosis. In contrast, desatu-
Table IV. Correlations of CPET parameters at enrolment with those of resting lung function 
tests and with standard follow-up parameters of SSc.
Results of the Pearson’s correlation tests with baseline CPET results. 
CPET parameters  Resting lung function Standard follow-up parameters Correlation
at enrolment parameter at enrolment  (including changes in resting  (Pearson’s r)
  lung function parameters) (p<0.05)
WR DLCO (% pred)  +0.60 
 DLCO (ml/min/mmHg)  +0.77
 FVC (L)  +0.76
VO2 DLCO (% pred)   + 0.52 
 DLCO (ml/min/mmHg)  +0.76
 FVC (L)  +0.72
  DeltaFVC/year (%pred) - 0.43 
  DeltaFVC/year (L) -0.42 
VO2/kg FVC (L)  +0.33
 DLCO (ml/min/mmHg)  +0.46
VE DLCO (%pred)  +0.45
 DLCO (ml/min/mmHg)  +0.58
 FVC (L)  +0.58
AT DLCO (%pred)  +0.40
 DLCO (ml/min/mmHg);  +0.61
 FVC  +0.44
  duration of Raynaud’s phenomenon +0.43
AT% DLCO (%pred)  +0.42
  duration of Raynaud’s phenomenon +0.41
  digital ulcers -0.44
VE/VO2 TLC (L)  -0.46
  DeltaPAP/year +0.73
VE/VCO2 DLCO (%pred)  -0.43
 DLCO (ml/min/mmHg)  -0.50
VE/VCO2  DeltaFVC/year (%pred) +0.58
  DeltaFVC/year (L) +0.57
DeltaSatmax  digital ulcers +0.53
For the explanation of the abbreviations, please refer to Materials and methods section, or the legends 
to Tables II and III. In the fourth column + Pearson’s r values mean positive correlation, whereas – 
means inverse correlation.
p<0.05 for all correlations presented in the Table.
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ration occurred less frequently in the 
patients who did not meet the endpoint 
(endpoint- patients) (p<0.05 with chi2 
test, odds ratio: 5.63 [CI: 1.08-29.38]).
The mean maximal desaturation at any 
CPET examination (i.e., the highest 
SpO2 reduction value during exercise) 
was actually higher in the endpoint- pa-
tients than in the endpoint+ group, but 
this is counterbalanced by the fact that 
the number of patients who experienced 
desaturation was lower in the endpoint- 
group (4 of 13 vs. 10 of 14). Logistic 
regression of baseline CPET values did 
not identify any CPET parameter to in-
dicate a significantly higher likelihood 
of the development of endpoint, but 
the annual change in desaturation dis-
played a near-significant risk (p=0.07). 
We also determined the specificity and 
sensitivity of the baseline CPET param-
eters to differentiate patients in whom 
a subsequent endpoint will evolve with 
ROC analysis, but none of the calculat-
ed cut-off values provided a statistically 
significant discriminative power. 
Since the CPET values displayed a 
significant variation within the cohort, 
including a considerable number of 
patients with markedly increased and 
decreased values, resulting in near-
normal mean values, we supposed that 
this may confound meaningful changes. 
In order to eliminate this problem, we 
have identified patients from the cohort 
with severely or moderately abnormal 
CPET results and compared them with 
the rest of the cohort. For this purpose, 
two groups were separated: 1.) patients 
with at least two measurement values 
below the 25th percentile of WR, VO2, 
VO2/kg, AT (L/min) or AT% at inclu-
sion (severely abnormal – n=4), and 
2.) patients with at least three results 
below the 50th percentile of the above-
mentioned parameters (moderately ab-
normal – n=10). Comparisons of these 
groups with the respective remaining 
parts of the cohort, however, revealed 
only one significant difference: the 
degree of desaturation/year proved to 
be on average negative (decreasing) 
in the patients with severely abnormal 
baseline CPET values (-1.0 [-1.2-0%]), 
whereas it increased in the rest of the 
cohort (1.15 [0.76-2.0]) (p=0.01). Age, 
disease duration, and poor prognostic 
values, including ILD, digital ulcer, 
need for immunosuppressive therapy 
and the composite endpoint were not 
different in any of the comparisons.
Finally, our data indicate that resting 
lung function parameters reflecting the 
lung parenchymal involvement (TLC, 
FVC) on average do not display a no-
ticeable change during follow-up in 
our cohort, and therefore the moderate 
decrease of DLCO at baseline (mean: 
57%) suggests that we should focus 
on pulmonary vascular involvement 
when assessing the value of CPET. We 
therefore separated the patients with 
either an increase of >3 mmHg in PAP 
or >2% decrease in DLCO annually 
(n=12), and compared their CPET re-
sults with the remaining patients. This 
comparison also revealed one remark-
able difference: VCO2 at baseline was 
markedly lower in the group of patients 
in whom these parameters subsequently 
worsened more rapidly (mean: 1.29 vs. 
1.66, p=0.06), indicating that CO2 out-
put might as well be a useful predictor 
of pulmonary vascular insufficiency.
Discussion
An unmet need in the management of 
SSc patients is the accurate early iden-
tification of patients with rapid disease 
progression and with a high risk of ir-
reversible organ damage and a conse-
quent poor prognosis. The diagnostic 
delay is still rather long in scleroderma, 
and therefore early signs of lung, heart 
or vascular involvement are detectable 
in many patients at diagnosis. However, 
the identification of patients for exam-
ple with progressive ILD – in contrast 
to those, in whom the initial interstitial 
lung changes remain relatively stable – 
typically requires repeated assessments 
of resting lung function, of the extent 
of involvement with HRCT, and of 
other clinical variables such as Rodnan 
skin score. Biomarkers (28-32) or 18 
fluoro-desoxy-glucose-positron-emis-
sion tomography (33) have also been 
tested for such purposes, but informa-
tion is still limited (34, 35).
In the present study, we did not wish to 
focus on specific organ involvements 
of SSc, but rather we intended to ex-
ploit the complexity of the evaluation 
of CPET, and hypothesised that it may 
thus provide prognostic information 
about multiple adverse disease out-
comes. We have, therefore designed a 
composite end-point in which the indi-
vidual parameters reflect the value of 
CPET to inform about the full spectrum 
of aerobic metabolism starting from 
oxygen uptake (deltaDLCO) through 
pulmonary and systemic circulation 
to tissue oxygenation (digital ulcers). 
Our end-point is somewhat arbitrary, 
Table V. Comparison of selected variables between the patient subgroups who met and who 
did not meet the composite end-point of unfavourable outcome.
 Endpoint + (n=16) Endpoint – (n=13)
Age 48.56 (16-64) 50.69  (29-62)
dcSSc/lcSSc 10/6  5/8
ILD 11  (69%) 5  (39%)
Digital ulcer 7  (44%) 5  (39%)
Calcinosis 2  (6%) 1  (8%)
PAP 28.82  (18-44) 28.22  (24-35)
DeltaPAP/year 1.675  (-8 - 12) 0.6083  (-0.4-2)
DLCO  58  (31-94) 55  (20-79)
WR 107.6 (46-187) 93.17  (66-126)
VO2 (L/min) 1.45  (0.5-2.40) 1.21  (0.96-1.69)
VCO2 (L/min )   1.54  (0.45-2.53) 1.43  (1.10-1.85)
VO2/kg (ml/min/kg) 19.47  (9.5-28.2) 19.85  (14.2-36.5)
VE (L/min) 52.19  (17.6-85.6) 50.4  (35.8-81)
VE/VCO2 32.73 (28-41) 33.8  (26-42)
AT (L/min) 1.01  (0.58-1.56) 0.99  (0.65-1.91)
AT (%  of VO2max,pred) 47.07 (27-66) 49.00  (37-76)
Decrease in SpO2 (%) 5.3  (3-12) 11.75  (7-20)*
Desaturation (n) 10  4*
DeltaDesat/year (SpO2%) 1.07  (-1 – 2.5) 0.80  (-1.4-6.6)
Numbers indicate mean (range) or absolute number (percentage).
*p<0.05; p=0.07.
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but composite end-points are not at all 
unique in SSc research. Several stud-
ies have used combinations of death, 
event-free survival (the lack of major 
cardiovascular or pulmonary or renal 
complications), worsening in the Scle-
roderma-HAQ functional index, time 
until major organ damage, or initia-
tion of parenteral prostanoid therapy or 
long-term oxygen therapy due to wors-
ening of PAH as components of com-
posite end-points (36-39). In addition, 
our outcome measures have widely 
been used as single end-points in SSc 
studies too (40-44). We have found that 
the detection of desaturation at the first 
CPET examination, at the beginning of 
the follow-up indicates worse overall 
prognosis, i.e. the development of the 
composite end-point. Higher degree of 
desaturation at onset also predicted the 
development of digital ulcers, as well as 
a more rapid worsening of DLCO, and 
a faster subsequent increase in desatu-
ration at exercise, rendering the meas-
urement of oxygen saturation as a good 
indicator of the development of wors-
ening exercise capacity and cardiovas-
cular function. Patients with multiple 
and marked abnormalities in CPET (in 
particular, WR, VO2, VO2/kg and AT) at 
enrolment also have a higher likelihood 
to develop exercise-induced severe de-
saturation during follow-up. VCO2, AT 
and VE/VO2 also appear as useful pre-
dictors of selected outcome measures: 
low VCO2 appeared as an indirect indi-
cator of the development of pulmonary 
vascular insufficiency. Low AT at base-
line correlated with the development 
of digital ulcers and high VE/VO2 with 
that of pulmonary hypertension.
CPET parameters also correlated well 
with many of the standard resting as-
sessment tools, indicating that this test 
is feasible in SSc patients too. It is im-
portant to note that CPET provides a 
general overview about the state of the 
aerobic metabolism, and is influenced 
by ventilation, alveolo-capillary gas-
exchange, systemic and pulmonary cir-
culation, cardiac output, microvascular 
capillary structure and flow and the state 
of intracellular oxidative processes. Al-
though some CPET parameters can be 
more or less associated with specific 
organ dysfunction (23), it is considered 
more useful to predict survival or gen-
eral function, as it has been shown in 
lung-transplant patients (7) or chronic 
obstructive pulmonary disease (6). This 
is the reason why we have constructed 
a composite endpoint of frequent and 
widely-used cardiovascular or pulmo-
nary complications or death.
Our study indicated that CPET can pro-
vide additional information to identify 
SSc patients in whom the disease could 
run a progressive course and a poor 
prognosis may develop. If SSc patients 
display desaturation during exercise, 
they have a higher likelihood to experi-
ence progressive ILD, PH or peripheral 
vascular lesions. Importantly, standard 
resting lung function and echocardio-
graphic parameters were insufficient to 
predict the development of such unfa-
vourable outcome. This makes CPET 
a promising non-invasive examination 
method to estimate the progression of 
SSc. 
Several clinical parameters, includ-
ing diffuse cutaneous subset, various 
autoantibody-positivities, the presence 
of ILD or increased PAP at presenta-
tion have been proven to be helpful in 
identifying patients who need a closer 
follow-up and more aggressive therapy 
(1, 2, 4, 25-27). The value of decreased 
or decreasing DLCO or FVC and el-
evated or progressively increasing PAP 
to select patients at risk of high morbid-
ity or mortality has also been convinc-
ingly confirmed and regular measure-
ment of these parameters is strongly 
advocated during the follow-up of SSc 
patients (25, 26, 45). Our cohort in-
cluded consecutive SSc patients with 
heterogeneous, but often relatively mild 
clinical presentation, and patients with 
advanced cardiopulmonary or other 
organ damage were excluded. Most of 
the patients had relatively short disease 
duration since the first non-Raynaud 
symptom. Although the follow-up time 
was acceptably long, these factors, to-
gether with the fact that the cohort is 
not as high as those in whom the above-
mentioned predictive factors were 
identified, may explain why we did 
not find the standard clinical and lung 
function tests or echocardiography to 
show a significant correlation with the 
occurrence of the serious outcome end-
point. With these limitations in mind, 
it is even more noteworthy that vari-
ous CPET parameters, being strongly 
linked to oxygen utilisation, were able 
to discriminate between patients with or 
without endpoint (desaturation during 
exercise), or to correlate with adverse 
clinical outcomes, such as a more rapid 
decline in FVC or increase in PAP, or 
the development of digital ulcers (VO2, 
VE/VCO2, VE/VO2, desaturation and 
anaerobic threshold). 
There is a number of studies that have 
previously already addressed the value 
of CPET in SSc (11-22). Unlike our 
investigation, these studies have ad-
dressed almost exclusively two is-
sues: First, they have searched whether 
CPET can help to discriminate among 
causes of reduced exercise capacity in 
SSc, and found certain CPET param-
eters to be associated with pulmonary 
vasculopathy, left ventricular dysfunc-
tion or respiratory limitation, respec-
tively (12, 13, 15, 16), in some cases 
even in those patients in whom resting 
lung function tests and echocardiog-
raphy failed to disclose such evident 
causes. The other area of research was 
to assess whether CPET may aid in the 
detection of PAP in SSc patients (11, 
14, 18, 19). Dumitrescu et al. have pro-
spectively analysed 173 SSc patients, in 
whom PAP was verified by right heart 
catheterisation, and found peakVO2 and 
VE/VCO2 to show the highest correla-
tions with PAP, transpulmonary pres-
sure gradient and pulmonary vascular 
resistance (11). Of several parameters 
with high sensitivity and specificity for 
PH detection, peakVO2 showed highest 
diagnostic accuracy (sensitivity 87.5%, 
specificity 74.8% at a threshold level 
of 13.8 mL/min/kg). These investiga-
tions confirm that CPET is a feasible 
examination in SSc patients too, simi-
larly to chronic lung disease patients. 
However, the above-cited publications 
concluded that although CPET adds 
certain benefits during the work-up of 
dyspnea or fatigue in SSc, the standard 
assessment techniques, such as HRCT, 
resting echocardiography or right heart 
catheterisation for the verification of 
the particular cardiopulmonary organ 
manifestations are still not replaced by 
CPET. Since the highest value of CPET 
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is that it provides a comprehensive 
overview about oxygen utilisation from 
the alveolo-capillary gas exchange to 
cellular metabolism, we have decided 
to set up endpoints that are the most 
relevant to patient mortality and mor-
bidity, rather than to analyse individual 
organ involvements. Indeed, data about 
the value of CPET to assess functional 
outcome or survival in SSc patients 
is rather limited. We have found two 
publications about the association of 
between composite functional indices 
and CPET: Cuomo et al. have found 
that VO2/kg was the only parameter 
that showed a significant correlation 
between the HAQ-DI functional index 
and various CPET parameters (20), 
whereas in another study, VE/VCO2 
correlated positively with both the Dis-
ease Activity Index and the Disease Se-
verity Scale (21). One further study ex-
amined the connection between CPET 
and patient survival. Similarly to our 
results, Swigris et al. also demonstrated 
that desaturation (a drop in SpO2max 
below 89% or >4 percentage points) 
increased the risk of death during a me-
dian follow-up of 7.1 years, but it has to 
be noted that this study focused exclu-
sively on SSc patients with interstitial 
lung disease, and it was a retrospective 
study (22). The recently published pro-
spective follow-up study on the patients 
from the PHAROS registry, although 
it did not apply CPET, also confirmed 
that desaturation on exercise (6 minute 
walking test) is a predictor of mortality 
in SSc (46).
Our study has some weaknesses and 
strengths. The patient number is not 
as high as in many previous examina-
tions especially in multicentre cohorts, 
but still it was sufficient for the iden-
tification of some statistically signifi-
cant findings. We did not include right 
heart catheterisation in the protocol to 
corroborate the measurement of pul-
monary arterial pressure with this most 
accurate method because, as we men-
tioned, our primary aim was not to fo-
cus on PH, and because most of the pa-
tients had relatively early disease with 
no significant risk factors for PH, and 
we decided that right heart catheteri-
sation was not indicated and ethically 
established. However, we did perform 
right heart catheterisation in patients 
in whom the estimated PAP was >50 
mmHg, and there was only one such 
patient in this cohort. A strength of the 
investigation is that to our knowledge, 
this is the first study with prospective 
follow-up of SSc patients and repeat-
ed CPET examinations, so we could 
provide data about the time-course of 
CPET parameters during several years 
of follow-up in SSc. Unlike most of the 
previous studies, we did not selectively 
analyse various organ manifestations in 
SSc, but concentrated on the most cru-
cial outcomes of SSc, and we believe 
that such approach could help to cor-
rectly define the place of CPET in the 
care of SSc patients: to predict the ap-
pearance of complications that are re-
lated to oxygen-dependent processes, 
from tissue necrosis and PAP to patient 
survival. 
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